Innovative traditional Chinese medicine drugs may usher in an outbreak, and several major bottlenecks remain to be resolved

[Pharmaceutical Network Market Analysis] On March 29, the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" was released.
The plan mentioned the establishment of a high-level traditional Chinese medicine inheritance protection and technological innovation system, and reform and improvement of traditional Chinese medicine registration management
.

This will help further stimulate the research and development of new traditional Chinese medicine drugs, and it is expected that innovative traditional Chinese medicine drugs may usher in an outbreak
.

Capturing the changes in the traditional Chinese medicine industry under favorable policies, recently, securities companies including Minsheng Securities, Huaan Securities, Great Wall Securities, and Capital Securities have all released research reports expressing their optimism about the development of the traditional Chinese medicine sector.
medicine
.

For example, Debon Securities stated that "innovation of traditional Chinese medicine and the modernization of traditional Chinese medicine are the core development directions in the future"; Hua'an Securities Research Report pointed out that in 2021, innovative traditional Chinese medicine drugs will usher in an outbreak, and a total of 12 new traditional Chinese medicine drugs have been approved, more than the sum of the past four years
.

Not only is the classification of traditional Chinese medicines simplified on the declaration side, and innovative traditional Chinese medicines are listed separately, but also in the medical insurance negotiation on the payment side, traditional Chinese medicines also have obvious advantages and moderate price reductions.
Companies with innovative traditional Chinese medicines will stand out
.

It is worth mentioning that the current development of traditional Chinese medicine is still facing some prominent bottlenecks, hindering the pace of high-quality development of the industry
.

First, there is a lack of high-quality Chinese medicine talents
.

The development of the modernization of traditional Chinese medicine is inseparable from a high-quality talent team.
However, at present, because the education of traditional Chinese medicine is mainly based on higher education, and the standards and evaluation system of Western medicine are still used, many students start late, and the clinical time is short.
Obviously insufficient, the overall strength is relatively weak, resulting in a general lack of high-quality talents in the industry
.

In this regard, the industry suggests that the growth law of TCM talents should be followed, talents with TCM thinking and rich clinical practice experience of TCM should be cultivated, and the evaluation and incentive mechanism of TCM talents should be further improved
.

 　　Second, the technology of traditional Chinese medicine equipment is still relatively backward
.

The development of traditional Chinese medicine is inseparable from the upgrading of equipment
.

At present, the traditional Chinese medicine technical equipment industry still has difficulties such as low investment in research and development, lack of research talents, limited key technologies, and backward enterprise management
.

However, as the key supporting role of traditional Chinese medicine equipment has become prominent, relevant support policies have continued to be introduced in recent years to help the innovation and development of traditional Chinese medicine equipment technology
.

 　　Third, because it is difficult to obtain international recognition for clinical efficacy and safety, it is difficult for traditional Chinese medicine to go global
.

The evidence dilemma of evidence-based medicine is a major evidence threshold for traditional Chinese medicine
.

In this regard, the industry suggests that the research on the treatment of dominant diseases with proprietary Chinese medicines should be strengthened, and modern scientific and technological means should be used to clarify the theory of traditional Chinese medicine, and to prove the clinical efficacy and safety of the products
.

For example, in order to break through the "bottleneck" of Chinese medicine going overseas, some Chinese medicine companies not only carry out a number of evidence-based medical research in China, but also choose to cooperate with many large international medical research institutions abroad to carry out research on related Chinese medicine products, and have achieved good results.
A large number of scientific research achievements have won the recognition of the international medical community
.

 　　In general, there is a long way to go to inherit and innovate traditional Chinese medicine
.

In order to solve the bottleneck restricting the development of the modernization of traditional Chinese medicine, many parties such as traditional Chinese medicine enterprises and traditional Chinese medicine pharmaceutical equipment enterprises still have some way to go
.

Only through the thorns can you meet the stars and the sea in front of the road
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.